The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

Bloomfield-based Cigna announced this week a new initiative that aims to reduce out-of-pocket prescription-drug costs and make those costs more transparent.

In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and Blue Shield Plans, was found guilty of engaging in horizontal price-fixing in collaboration with Express Scripts,

Eagan-based Prime Therapeutics has been ordered to pay $10 million in damages after federal arbitration found it engaged in illegal price fixing with competitor Express Scripts to suppress drug reimbursement rates for HIV/AIDS treatments.

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent — for billions in profits, according to a report from the Federal Trade Commission,

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market. Meanwhile, the price patients pay for drugs has increased nearly 300% in the last 30 years, according to Peterson-KFF Health System Tracker.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two

The lawsuit comes just after Cigna/Express Scripts filed a legal pre-emptive strike of its own, seeking a retraction of the FTC's report on the sector and accusing the financial regulator of ...

As the rising cost of insulin continues to make it difficult for so many diabetic patients to receive life-saving care, Insulin Outlet is stepping up to help by providing safe, affordable, and accessible insulin to those who need it most.

Oil and gas production in the United States is hitting record highs, easily outpacing consumption growth and fueling an export boom that in 2020 achieved the country’s first trade surplus in energy since at least the 1950s.

Evercore ISI has updated its outlook on CVS Health (NYSE:CVS) shares, raising the price target from $60.00 to $65.00 while maintaining an Outperform rating. The adjustment comes in anticipation of future performance dynamics,